Treatment of the Kras and Trp53 mutant pancreatic cancer (KPC) cell line — a genetically engineered mouse model (KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx1-Cre) — with MTRX133 downregulated the expression of key glycolysis-related genes, including SLC2A1, HK2, PFK, ENO1, LDHA, and SLC16A3 (Figure 2G and Supplemental Figure 2C). This evidence concerns the gene KRAS and familial pancreatic carcinoma.